PExA partnering in research project for increased understanding of the work environment within the 3D printing industry
(This information is translated by Google Translate)
Recently, an interdisciplinary project called NanoSafety 2 has started in Örebro. The project is a collaboration between several companies in the 3D printing industry, Occupational and Environmental Medicine at the University Hospital in Örebro and Örebro University’s two research environments Human Technology Environment (MTM) and Inflammatory Response and Infection Susceptibility Center ( iRiSC ).
The project, which is financed by the KK Foundation, aims to investigate how small particles, so-called nanoparticles that arise in the 3D printing industry can affect the person who is exposed.
As part of previous research, personnel in the 3D printing industry have regularly submitted urine samples and blood samples, but in this new and in-depth project will also be allowed to submit breath samples in a PExA instrument. By now being able to use non-invasive collection of lung fluid for analysis of biomarkers, it is possible to follow how the innermost part of the lung is affected over time and degree of exposure.
The project has three goals: to detect risks, propose solutions and develop a research center for safety around the extremely small particles. To understand their size, it can be mentioned that there is a billion nanometers in an ordinary meter. Typical examples of naturally occurring nanoparticles are viruses and gas molecules.
Tomas Gustafsson, CEO at PExA comments
- We are pleased to be part of this collaboration between academia, society and industry that aims to understand how this new and fast-growing industry affects human health. It also shows the breadth of how our unique research instrument can be used to study the innermost parts of the lungs in everything from occupational health to lung cancer.
More information about the NanoSafety 2 project can be found at the link below :
For further information, please contact:
Tomas Gustafsson, E-mail: info@pexa.se
Also follow PExA on LinkedIn:
https://www.linkedin.com/company/pexa-ab/
About PExA AB:
PExA AB ( 556956-9246 ) has developed PExA 2.1, a patented research instrument that helps researchers to intelligently collect biological samples from the smallest airways through a simple exhalation maneuver. PExA’s technology is currently used by prominent research groups in several different countries and research with the instrument has resulted in approximately 40 scientific publications, which serve as reference material for PExA’s method. The company’s long-term goal is to market and sell diagnostic instruments for popular diseases (e.g. lung cancer and COPD) to be used globally for diagnosis or general screening at facilities where care is offered. The company intends at the time it is relevant to sell to clinics to have developed more patient-friendly, flexible and commercial products, which means that PExA addresses a significantly wider market, which today includes several million patients globally.
PExA’s B share is listed on the Spotlight Stock Market.